DPYD Multiplex 0% AF gDNA, tap a thumbnail to see more views.
DPYD Multiplex 0% AF gDNA
The SensID DPYD Multiplex 0% AF gDNA Reference Material consists of various dihydropyrimidine dehydrogenase gene (DPYD) variants that are known to have an impact on 5-fluorouracil (5-FU) catalyzation. 5-FU is used for treatment of cancer. In patients with defective DPYD, 5-FU toxicity occurs with standard doses of 5-FU causing severe and life- threatening effects. SensID DNA products are precisely quantitated using standard methods traceable to internationally certified reference material. The SensID DPYD- Multiplex 0% AF gDNA Reference Material consists of one vial with 0% mutant allele frequency. Well characterized human gDNA from proprietary cell line is used. For additional information see table 1 and 2.
Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.
This kit in detail
The SensID DPYD Multiplex 0% AF gDNA Reference Material consists of various dihydropyrimidine dehydrogenase gene (DPYD) variants that are known to have an impact on 5-fluorouracil (5-FU) catalyzation. 5-FU is used for treatment of cancer. In patients with defective DPYD, 5-FU toxicity occurs with standard doses of 5-FU causing severe and life- threatening effects.
SensID DNA products are precisely quantitated using standard methods traceable to internationally certified reference material. The SensID DPYD- Multiplex 0% AF gDNA Reference Material consists of one vial with 0% mutant allele frequency. Well characterized human gDNA from proprietary cell line is used. For additional information see table 1 and 2.
- Ideal for NGS workflows
- Mutations included
- Additional mutations covered
- Ideal for validations and development
- Analyzing performance NGS pipeline
Reference Materials for Pharmacogenetics (PGx)
SensID has created the DPYD Multiplex 0% AF gDNA, a completely platform-independent control for testing dihydropyrimidine dehydrogenase (DPYD; DHP; DPD; DHPDHASE). The selected variants were chosen based on research publications and recommendations from various working groups and key opinion leaders advocating for the adoption of DPYD testing. Regulatory bodies like the EMA and NHS recommend that all patients be screened for DPYD deficiency before undergoing systemic treatment with FU-containing drugs, including 5-fluorouracil (5-FU), Capecitabine, Tegafur, and Flucytosine. This product includes a set of gDNA with a mutation frequency of 0%, 50%, or 100%, along with a highly characterized genomic background. Mutations in the DPYD gene lead to DPYD deficiency, a metabolic disorder affecting pyrimidine breakdown, which is linked to thymine-uraciluria and an increased risk of toxicity in cancer patients treated with 5-fluorouracil-based chemotherapy.
Therapeutic areas where DPYD mutation status is significant:
– Colorectal cancer
– Gastric, pancreatic, and oesophageal cancers
– Breast cancer
– Squamous cell carcinoma of the head and neck
– Biliary tract cancers
– Non-small cell lung cancer (NSCLC)
– Systemic yeast and fungal infections caused by sensitive organisms
The DPYD Multiplex 0% AF gDNA is perfectly suited for Next Generation Sequencing (NGS) workflows, especially for:– Validation and development of sequencing methods (e.g., Whole Exome Sequencing (WES), Amplicon Sequencing) and PCR techniques
– Calibration and optimization of instruments and workflows for DNA processing (e.g., DNA fragmentation via acoustic shearing, enzymatic digestion, or sonication)
– Assessing the performance of your NGS pipeline by comparing it with freely available datasets.
- DPYD Multiplex 0% AF gDNA
Product is ready-to-use.
Datasheets and regulatory documentation
Everything your quality team needs for evaluation and procurement.
Instruction for Use
Frequently paired with this kit
Other assays and instruments lab teams add alongside the DPYD Multiplex 0% AF gDNA.
Add this kit to your quote
Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.
